Last reviewed · How we verify
GSK Biologicals' investigational vaccine GSK1562902A
GSK Biologicals' investigational vaccine GSK1562902A is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.
At a glance
| Generic name | GSK Biologicals' investigational vaccine GSK1562902A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children (PHASE2)
- Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Biologicals' investigational vaccine GSK1562902A CI brief — competitive landscape report
- GSK Biologicals' investigational vaccine GSK1562902A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK Biologicals' investigational vaccine GSK1562902A
What is GSK Biologicals' investigational vaccine GSK1562902A?
GSK Biologicals' investigational vaccine GSK1562902A is a Biologic drug developed by GlaxoSmithKline.
Who makes GSK Biologicals' investigational vaccine GSK1562902A?
GSK Biologicals' investigational vaccine GSK1562902A is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is GSK Biologicals' investigational vaccine GSK1562902A in?
GSK Biologicals' investigational vaccine GSK1562902A is in Phase 2.